Status:

UNKNOWN

The Effect of Probiotic Supplementation on the Mental Status, Inflammation, and Intestinal Barrier in Major Depressive Disorder Patients Using Gluten-free or Gluten-containing Diet

Lead Sponsor:

Medical University of Lublin

Collaborating Sponsors:

Sanprobi Sp. z o.o., Sp. k., Szczecin, Poland

Conditions:

Depressive Disorder, Major

Depression

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

More and more evidence confirms the relationship between the gut-brain-microbiota axis and the symptoms of mood disorders. A potential pathway connecting the intestines and the brain in depression is ...

Eligibility Criteria

Inclusion

  • Outpatients aged 18-60 years old;
  • Signed written Informed Consent Form;
  • Meet the DSM-5 criteria for MDD;
  • Body mass index (BMI) ≥18.5 kg/m2 and ≤30 kg/m2;
  • MADRS (Montgomery-Asberg Depression Scale) total score at screening (V0) and at baseline (V1) of 20 points or more (moderate or severe depression);
  • A willingness and motivation to follow the study protocol.

Exclusion

  • Diagnosis of autoimmune, neurological, immunocompromised, thyroid, inflammatory bowel diseases, diabetes, cancers, and/or IgE-dependent allergy;
  • Psychiatric comorbidities (except specific personality disorder) including mental retardation, organic brain dysfunction, or addiction (except nicotine and caffeine);
  • High risk of suicide in the investigator's opinion;
  • An infection one month before the study baseline visit (V1);
  • The use of antibiotics and/or probiotics three months prior to the study;
  • Glucocorticosteroids and/or metformin treatment;
  • Intake of any other drugs which in the investigator' opinion may affect the results of study;
  • Intake of any dietary supplementation (except for vitamin D according to the "Vitamin D supplementation guidelines, 2018") which in the investigator' opinion may affect the results of the study;
  • Changes in a pharmacotherapy and/or psychotherapy of MDD 2 weeks before the trial entry;
  • Electroconvulsive therapy (ECT) 12 months before the trial entry;
  • No specific diet (e.g., elimination, vegan, reduction) and changes in physical activity 4 weeks before the trial entry;
  • Pregnancy or lactation.

Key Trial Info

Start Date :

April 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2021

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT03877393

Start Date

April 1 2019

End Date

February 1 2021

Last Update

March 15 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

1st Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin

Lublin, Poland, 20439